Advanced Filters
noise
Found 811 clinical trials
M Martha Forloines, PhD

Senicapoc in Alzheimer's Disease

Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity and target engagement in humans …

55 - 85 years of age All Phase 2
F Francesco Sardanelli

White Matter Hyperintensities in Amnestic Mild Cognitive Impairment or Alzheimer's Disease

This study focuses on assessing and measuring white matter hyperintensities in individuals with amnestic mild cognitive impairment (aMCI) or Alzheimer's disease. Objective The primary objective of the study is to quantify the extent and distribution of white matter hyperintensities in the brains of individuals diagnosed with amnestic mild cognitive impairment …

65 years of age All Phase N/A
A Amy Hughes, AAS

Brain Energy for Amyloid Transformation in Alzheimer's Disease Study

The Brain Energy for Amyloid Transformation in AD (Alzheimer's disease) or BEAT-AD study will compare the effects of a ketogenic low-carbohydrate diet and a low-fat diet in adults with mild cognitive impairment. The data collected will help determine whether diet interventions induce changes in cognitive function, cerebral blood flow, and …

55 - 85 years of age All Phase N/A
A Amala Soumyanath, PhD

Safety and Target Engagement of Centella Asiatica in Cognitive Impairment

This clinical trial is focused on determining whether biological signatures of target engagement by a Centella asiatica water extract product administered orally for 6 weeks can be measured in comparison to placebo. This study will also assess the safety and tolerability of the Centella asiatica water extract product.

60 - 85 years of age All Phase 1
M Maïté Formaglio, PH

Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease

The validation of biomarkers allowing the discrimination of cognitive and behavioral disorders of psychiatric origin from those of neurodegenerative origin would facilitate diagnosis and improve patient management. Neurofilaments, which are markers of neuronal lysis, appear to be a promising biomarker. In a previous preliminary study, the investigators demonstrated significantly lower …

45 - 80 years of age All Phase N/A
A Andrea Davis, MS

A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment

This is a first-in-human clinical trial to test whether a protein administered into the brain continuously by gene therapy, Brain-Derived Neurotrophic Factor (BDNF), will slow or prevent cell loss in the brains of people affected by Alzheimer's disease and Mild Cognitive Impairment. The protein may also activate cells in the …

50 - 80 years of age All Phase 1
K Kyurim Kang, PhD

Music Therapy for Patients With Alzheimer's Disease

This study is designed to assess the feasibility that individualized reminiscence-based virtual music therapy sessions can enhance autobiographical memory, mood, and cognition in patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD). 60 patients with MCI or mild dementia due to AD will receive two …

18 - 89 years of age All Phase N/A
M Mitzi Gonzales, PhD

Rapamycin - Effects on Alzheimer's and Cognitive Health

This study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin treatment in older adults with amnestic mild cognitive impairment (aMCI) and early stage Alzheimer's disease (AD).

55 - 89 years of age All Phase 2
P Paula Desplats

TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology in patients diagnosed with Mild Cognitive Impairment (MCI) or early to moderate Alzheimer's disease (AD). It will also learn about …

60 years of age All Phase 1

Memory Enhancement Using Transcranial Alternating Current Stimulation

The 32 million Alzheimer's disease (AD) and 69 million prodromal AD patients worldwide contribute to a large economic burden. Effective and safe therapies that slow or prevent the progression from mild cognitive impairment (MCI) to AD are therefore of high priority. Transcranial alternating current stimulation (tACS) is a safe and …

18 years of age All Phase N/A

Simplify language using AI